Major U.S. indices closed higher on Wednesday, with the Dow Jones Industrial Average rising 0.22% to 53,463.05, the S&P 500 gaining 0.21% to 7,707.98 and the Nasdaq advancing 0.16% to 26,331.09.
These are the top stocks that gained the attention of retail traders and investors through the day:
Moderna Inc. (NASDAQ:MRNA)
Moderna’s stock skyrocketed by 176.97%, closing at $174.38. The stock hit an intraday high of $176.66 and a low of $114.46, marking a new 52-week high. In the after-hours session, the stock fell 4.65% to $166.26.
Moderna shares surged after its personalized mRNA cancer vaccine with Merck succeeded in a Phase 3 melanoma trial, marking the first Phase 3 win for an mRNA-based cancer treatment. The result could shift investor perception of Moderna from a post-pandemic vaccine maker toward a potential oncology platform.
Webull Corp (NASDAQ:BULL)
Webull’s shares rose by 8.95%, closing at $8.64. The stock reached an intraday high of $8.70 and a low of $7.91.The stock shot up 14.01% to $9.85 in extended trading.
Webull reported second-quarter revenue of $198.83 million, up 51% year-over-year and above the $181.26 million estimate, while adjusted EPS of 5 cents beat expectations of 3 cents. Customer assets rose 79% to $28.5 billion, registered users reached 28.2 million and funded accounts climbed to 5.13 million.
Bitmine Immersion Technologies Inc. (NYSE:BMNR)
Bitmine’s stock climbed 10.72%, closing at $20.24. The stock’s intraday high was $20.90, with a low of $18.37. The stock rose 6.47% to $21.55 in after-hours trading.
The rise is attributed to the momentum in digital asset markets, as Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) prices surged. Bitmine’s treasury of crypto, cash, and investments reached $11.4 billion.
Strategy Inc. (NASDAQ:MSTR)
Strategy’s Class A shares increased by 12.68%, closing at $104.25. The stock reached a high of $106.90 and a low of $94.30. In extended trading, the stock rose 3.73% to $108.13.
The rally is linked to a broader crypto surge and falling Treasury yields, which have boosted investor interest in riskier assets.
Merck & Co. (NYSE:MRK)
Merck’s stock rose by 12.60%, closing at $152.20. The stock hit an intraday high of $153.50 and a low of $144.90.
The increase is tied to its collaboration with Moderna on the successful cancer therapy trial. This partnership has been pivotal for both companies.
Benzinga Edge Stock Rankings indicate Moderna stock has a Momentum score in the 95th percentile.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: vectorfusionart on Shutterstock.com
